Liminatus Pharma, Inc. (LIMN)
NASDAQ: LIMN · Real-Time Price · USD
24.22
-0.38 (-1.54%)
At close: Jun 6, 2025, 4:00 PM
23.26
-0.96 (-3.96%)
Pre-market: Jun 9, 2025, 4:02 AM EDT

Liminatus Pharma Income Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
FY 2024 FY 2023 FY 2022
Period Ending
Dec '24 Dec '23 Dec '22
Selling, General & Admin
0.651.060.86
Research & Development
2.693.761.85
Operating Expenses
3.334.822.71
Operating Income
-3.33-4.82-2.71
Interest Expense
-0.34-0.18-0.22
Interest & Investment Income
0.120.01-
Pretax Income
-3.55-4.98-2.93
Net Income
-3.55-4.98-2.93
Net Income to Common
-3.55-4.98-2.93
Shares Outstanding (Basic)
11210236
Shares Outstanding (Diluted)
11210236
Shares Change (YoY)
9.49%188.25%-
EPS (Basic)
-0.03-0.05-0.08
EPS (Diluted)
-0.03-0.05-0.08
EBIT
-3.33-4.82-2.71
Source: S&P Global Market Intelligence. Standard template. Financial Sources.